MBX Biosciences Files 2024 Proxy Statement
Ticker: MBX · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1776111
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
TL;DR
MBX Proxy Statement is IN. Get ready for shareholder votes.
AI Summary
MBX Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for the fiscal year ending December 31, 2024. The filing, which does not require a fee, outlines the company's governance and shareholder matters. MBX Biosciences is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides shareholders with crucial information regarding company operations, executive compensation, and voting matters, enabling informed participation in corporate decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- MBX Biosciences, Inc. (company) — Registrant
- 0000950170-25-056978 (filing_id) — Accession Number
- 20250423 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxy votes from shareholders for an upcoming annual or special meeting.
When was this proxy statement filed by MBX Biosciences, Inc.?
MBX Biosciences, Inc. filed this definitive proxy statement on April 23, 2025.
What is the fiscal year end for MBX Biosciences, Inc. as stated in the filing?
The fiscal year end for MBX Biosciences, Inc. is December 31.
Does MBX Biosciences, Inc. have any associated filing fees for this document?
No fee is required for this filing, as indicated by the 'No fee required' checkbox being selected.
What is the Standard Industrial Classification (SIC) code for MBX Biosciences, Inc.?
The SIC code for MBX Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding MBX Biosciences, Inc. (MBX).